Abu Dhabi, UAE — Mubadala Investment Company, an Abu Dhabi sovereign investor, has entered into a definitive agreement to acquire KELIX bio, a specialty pharmaceutical business focused on delivering complex generics across emerging markets.
KELIX bio was incepted in November 2020, and has since acquired manufacturing businesses in India, Egypt, Malta and Morocco, commercializing a broad range of both oral and injectable formulations covering diverse therapy areas including diabetes, oncology, cardiology, and central nervous systems.
With Kelix bio specializing in relevant therapy areas and a leadership team experienced in successful buy-and-build strategies globally, the move aligns with Mubadala’s goal to position the UAE prominently in the global life sciences sector, Mubadala said.
Dr. Bakheet Al Katheeri, Chief Executive Officer of Mubadala’s UAE Investments Platform, said, “In line with our role as a responsible investor, today’s acquisition is testament to the role Mubadala continues to play in accelerating the nation’s economic diversification through our portfolio companies and national champions.”
Hocine Sidi-Said, co-founder, and Chief Executive Officer at KELIX bio, said, “We are immensely grateful to our previous shareholders for their faith in our vision and for supporting a fast-paced acquisition programme since inception. With Mubadala’s acquisition of KELIX bio, we embark into an exciting journey that promises to deliver not only economic returns but also cause a durable societal impact in the United Arab Emirates. We are excited to augment the manufacturing capabilities of the nation and drive an innovation agenda in diabetes, oncology, and biologics to name a few.”
